IMPACT OF DELAYED TREATMENT INITIATION WITH RESMETIROM IN PATIENTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED FIBROSIS

被引：0
|
作者：
Ansaripour, A. [1 ]
Kim, Y. [2 ]
Montero, M. Gomez [1 ]
Hosmane, S. [2 ]
机构：
[1] Optimax Access, Rotterdam, ZH, Netherlands
[2] Madrigal Pharmaceut, Jersey City, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE511
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
    Noureddin, Mazen
    Charlton, Michael R.
    Harrison, Stephen A.
    Bansal, Meena B.
    Alkhouri, Naim
    Loomba, Rohit
    Sanyal, Arun J.
    Rinella, Mary E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (12) : 2367 - 2377
  • [2] COST-EFFECTIVENESS ANALYSIS OF RESMETIROM FOR THE TREATMENT OF ADULTS WITH NONCIRRHOTIC NASH AND MODERATE-TO-ADVANCED LIVER FIBROSIS IN THE US: INTEGRATING THE DUAL NASH RESOLUTION AND FIBROSIS IMPROVEMENT ENDPOINTS
    Kim, Y.
    Smith, Z.
    Mitchell, D.
    Johnson, S.
    VALUE IN HEALTH, 2024, 27 (12) : S122 - S122
  • [3] FDA approves Resmetirom: groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis
    Waheed, Aiman
    Gul, Muhammad H.
    Shabbir, Muhammad U. B.
    Raja, Hafsa A. A.
    Wardak, Abdul B.
    Hussaini, Helai
    Shah, Yash
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (03): : 1088 - 1091
  • [4] Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH)
    Ratziu, Vlad
    Sanyal, Arun J.
    Loomba, Rohit
    Caldwell, Stephen H.
    Ghalib, Reem H.
    Torres, Dawn M.
    McCullough, Arthur J.
    Muir, Andrew J.
    Myers, Robert P.
    Schall, Raul E. Aguilar
    Subramanian, Mani
    McHutchison, John G.
    Bosch, Jaime
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    HEPATOLOGY, 2015, 62 : 1298A - 1299A
  • [5] CLINICAL AND HISTOLOGICAL DETERMINANTS OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS IN THE ELDERLY
    Noureddin, Mazen
    Vaughn, Ivana A.
    Neuschwander-Tetri, Brent A.
    Sanyal, Arun J.
    McCullough, Arthur J.
    Merriman, Raphael B.
    Yates, Katherine P.
    Tonascia, James
    Unalp-Arida, Aynur
    Doo, Edward
    Kleiner, David E.
    Behling, Cynthia A.
    Loomba, Rohit
    HEPATOLOGY, 2011, 54 : 1118A - 1118A
  • [6] Clinical and biochemical predictors of advanced hepatic fibrosis in nonalcoholic steatohepatitis (NASH).
    Chitturi, S
    Fung, C
    Farrell, GC
    Samarasinghe, D
    Lin, R
    Liddle, C
    George, J
    HEPATOLOGY, 2000, 32 (04) : 535A - 535A
  • [7] Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
    Younossi, Zobair M.
    Stepanova, Maria
    Sanyal, Arun J.
    Harrison, Stephen A.
    Ratziu, Vlad
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Afdhal, Nezam H.
    Abdelmalek, Manal F.
    Bosch, Jaime
    Goodman, Zachary D.
    HEPATOLOGY, 2017, 66 : 1171A - 1171A
  • [8] Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
    Fishman, Jesse
    Kim, Yestle
    Parise, Helene
    Bercaw, Eric
    Smith, Zachary
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1108 - 1118
  • [9] Baseline characteristics of patients with and without diabetes in trials for advanced fibrosis/cirrhosis due to nonalcoholic steatohepatitis (NASH)
    Romero-Gomez, M.
    Calleja, J.
    Crespo, J.
    Garcia-Samaniego, J.
    Augustin, S.
    Turnes, J.
    Younossi, Z. M.
    Eric, L. J.
    Wong, V. W.
    Okanoue, T.
    Trauner, M.
    McColgan, B. J.
    Harrison, S. A.
    Quentin, A. M.
    DIABETOLOGIA, 2019, 62 : S529 - S530
  • [10] CHANGES IN FIBROSIS, BUT NOT THE NAFLD ACTIVITY SCORE (NAS), ARE ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS
    Sanyal, Arun
    Harrison, Stephen A.
    Ratziu, Vlad
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Caldwell, Stephen H.
    Shiffman, Mitchell L.
    Aguilar, Raul
    Jia, Catherine
    McColgan, Bryan J.
    Natha, Macky
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John
    Muir, Andrew J.
    Afdhal, Nezam H.
    Bosch, Jaime
    Goodman, Zachary
    GASTROENTEROLOGY, 2017, 152 (05) : S1055 - S1055
12345